(Q38223208)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Osteogenesis imperfecta: diagnosis and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

main subject

osteogenesis imperfecta

0 references

author

Andrew Biggin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

C F Munns

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

1 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

Current osteoporosis reports

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

279-288

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24964776%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11914-014-0225-0

21 March 2020

exact match

0 references

cites work

Genetic heterogeneity in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

New perspectives on osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Natural history of hyperplastic callus formation in osteogenesis imperfecta type V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

PPIB mutations cause severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Nosology and classification of genetic skeletal disorders: 2010 revision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Etiology of osteogenesis imperfecta: an overview of biochemical and molecular genetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Static and dynamic bone histomorphometry in children with osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Management of the adverse effects associated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Clinical review 1: Bisphosphonate use in childhood osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

The use of bisphosphonates in children: review of the literature and guidelines for dental management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Safety of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Does treatment with bisphosphonates endanger the human pregnancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Experience with the Fassier-Duval telescopic rod: first 24 consecutive cases with a minimum of 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Surgical treatment of osteogenesis imperfecta: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Emerging therapeutic approaches for osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-014-0225-0

Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease

21 January 2018

1 reference

12 December 2020

Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta

1 reference

12 December 2020

Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age

1 reference

12 December 2020

Preliminary results on the mobility after whole body vibration in immobilized children and adolescents.

1 reference

12 December 2020

Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management

1 reference

12 December 2020

Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics

1 reference

12 December 2020

Clinical management of osteogenesis imperfecta

1 reference

12 December 2020

First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI

1 reference

12 December 2020

Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2

1 reference

12 December 2020

Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management

1 reference

12 December 2020

Bisphosphonate therapy for osteogenesis imperfecta

1 reference

12 December 2020

A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta

1 reference

12 December 2020

Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment

1 reference

12 December 2020

Mutations in WNT1 are a cause of osteogenesis imperfecta

1 reference

12 December 2020

Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta

1 reference

12 December 2020

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment

1 reference

12 December 2020

Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta

1 reference

12 December 2020

Cellular and molecular mechanisms of action of bisphosphonates

1 reference

12 December 2020

Rehabilitation approaches to children with osteogenesis imperfecta: a ten-year experience

1 reference

12 December 2020